Navigation Links
AMS Announces Worldwide Launch of the Revolutionary MoXy™ Liquid Cooled Fiber for Fast, Safe Treatment of Enlarged Prostate
Date:9/30/2010

MINNETONKA, Minn., Sept. 30 /PRNewswire/ -- American Medical Systems® (AMS) (Nasdaq: AMMD), a leading provider of world-class devices and therapies for male and female pelvic health, today announced the worldwide launch of its revolutionary MoXy™ Liquid Cooled Fiber for laser treatment of benign prostatic hyperplasia (BPH) or enlarged prostate.

Designed to be used with the recently launched GreenLight XPS™ (Xcelerated Performance System) 180 Watt laser, the MoXy fiber, with its Active Cooling Cap™ technology, utilizes 360-degree saline flow to maintain the temperature of the fiber tip for dramatically increased fiber longevity. This combination is 50 percent faster in vaporization speed than the GreenLight HPS® (High Performance System) 120 Watt system, significantly reducing treatment time and operative cost. The new system maintains the same safety profile as the proven GreenLight HPS and PV systems, even with the increase in power.

The MoXy fiber is immediately available in the United States, Europe and Australia. Worldwide commercialization will continue throughout the remainder of 2010.

XPS with the MoXy fiber is the latest in AMS' world-class portfolio of innovative, technologically advanced solutions to treat a variety of pelvic health conditions. Through its commitment to innovation and continuous improvement, AMS has become the recognized technology leader in men's and women's pelvic health markets. For more information about GreenLight XPS and MoXy, visit www.AMSGreenLight.com.

About American Medical Systems:

American Medical Systems, headquartered in Minnetonka, Minnesota, is a diversified supplier of medical devices and procedures to cure incontinence, erectile dysfunction, benign prostatic hyperplasia (BPH), pelvic floor prolapse and other pelvic disorders in men and women. These disorders can significantly diminish one's quality of life and profoundly affect social relationships. In recent years, the number of people seeking treatment has increased markedly as a result of longer lives, higher quality-of-life expectations and greater awareness of new treatment alternatives. American Medical Systems' products reduce or eliminate the incapacitating effects of these diseases, often through minimally invasive therapies. The company's products were used to treat more than 335,000 patients in 2009.

More information about the company and its products can be found at www.AmericanMedicalSystems.com  and in the Company's Annual Report on Form 10-K for 2009 and its other SEC filings.


'/>"/>
SOURCE American Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... 23, 2017 ArisGlobal, a leading ... announces agClinical 3.3, the latest version of its comprehensive ... science organizations to confidently and efficiently meet new compliance ... the electronic trial master file so that compliance is ... ...
(Date:1/23/2017)... 2017  HOPE BIOSCIENCES announced today that it ... commercialize nuc -gemcitabine™ (APTA-12/HOPE-888) through a licensing ... nuc -Gemcitabine consists of Antisoma,s ... found on many cancer cells, and dFdCMP, an ... conjugates) or SMDCs (small molecule drug conjugates), which ...
(Date:1/23/2017)... 23, 2017  Therabron Therapeutics, Inc., a clinical-stage ... in respiratory care, today announced that the European ... has granted Orphan Drug Designation for Therabron,s CG367 ... Syndrome (BOS).  "We are pleased to ... to treat patients diagnosed with BOS following lung ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 23, 2017 , ... The TouchPoint Solution, ... who entered metrics into the product’s app. The data replicates and validates ... that within just 30 seconds of using Buzzies, people experienced a 74 percent ...
(Date:1/24/2017)... Michigan (PRWEB) , ... January 24, 2017 , ... The ... other advocates for drug and alcohol awareness, have worked with communities to designate the ... year, observed January 23-29, 2017, the theme is “Shatter the Myths.” As a ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... localization services for life science companies, has achieved ISO 17100:2015 certification following ... America. ISO 17100 is the globally recognized standard that establishes guidance for ...
(Date:1/23/2017)... ... 23, 2017 , ... The iaedp Foundation, recognized for its ... who treat the full spectrum of eating disorder problems, proudly announces the addition ... of the leading eating disorder treatments centers located throughout the U.S. As partners ...
(Date:1/23/2017)... ... 2017 , ... Sharon Kleyne, America’s leading water researcher, advocate and feared enemy ... of making new water infrastructure a number one priority. “As we usher in a ... infrastructure to become a top priority of our new political change agents.” Kleyne pointed ...
Breaking Medicine News(10 mins):